BIOMAT Database Logo BIOMAT Database Logo

[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer]. 1989

T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Dept. of Chemotherapy, Tokyo Metropolitan Komagome Hospital.

In a recent phase II trial we have shown a favorable response rate for sequential methotrexate-5-fluorouracil (MF) in advanced gastric and colorectal cancer. We determined the therapeutic effect of sequential MF in patients with advanced gastric cancer by comparing it to 5-fluorouracil alone (F) in a randomized multicenter trial. Since February 1987 to July 1988, 133 patients with advanced gastric cancer have been prospectively randomized to receive either MF (methotrexate 100 mg/m2 i.v. push, 5-fluorouracil 600 mg/m2 i.v. drip over 15 minutes one hour after methotrexate and leucovorin 15 mg p.o. q 6 hrs x 2 beginning 24 hrs after methotrexate) of F (the same 5-fluorouracil as described for MF). Each treatment was repeated weekly x 5, then q 2 weeks. The two treatment arms were balanced for 17 clinical characteristics. The response rate was 17.9% (10 of 56 patients) in the MF arm and 1.9% (one of 53 patients) in the F arm (p less than 0.01). Median duration of response was 6.8 weeks (MF) and 6 weeks (F), respectively. Median survival time was 7.9 months (MF) and 7.3 months (F) on interim findings. Leukocytopenia and GI toxicity were significantly more common in patients receiving MF, but the degree was similar for both arms. Other side effects were minimal and no different. This schedule of MF is more effective than F in inducing remission for patients with advanced gastric cancer.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions

Related Publications

T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
June 1991, American journal of clinical oncology,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil.
June 1987, American journal of clinical oncology,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer].
March 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
April 1981, Cancer,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
March 1995, Cancer,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.
November 1986, Cancer treatment reports,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone.
January 1987, NCI monographs : a publication of the National Cancer Institute,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.
October 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.
October 1988, European journal of cancer & clinical oncology,
T Sasaki, and K Ota, and J Ibayashi, and Y Sakata, and T Matsuoka, and M Ishikawa, and A Wakui, and K Ogoshi, and S Akazawa, and Y Sakai
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer].
August 1985, Gan no rinsho. Japan journal of cancer clinics,
Copied contents to your clipboard!